OBJECTIVES: An efavirenz-based antiretroviral therapy (ART) regimen is preferred for children more than 3 years of age with tuberculosis. However, rifampin, a key component of antituberculosis therapy, induces CYP2B6. An increased dose of efavirenz is recommended in adults weighing more than 50 kg who require rifampin, but there is scant information in children being treated for tuberculosis. DESIGN: Plasma efavirenz concentrations were compared in 40 children during concomitant treatment for tuberculosis and HIV-1, after stopping rifampicin, and in a control group of children without tuberculosis. Associations with antituberculosis treatment, metabolizer genotype (based on CYP2B6 516G→T, 983T→C, and 15582C→T), weight, and time after dose were evaluated. RESULTS: Compared to children with extensive metabolizer genotypes, efavirenz concentrations were increased 1.42-fold (95% confidence interval, CI 0.94–2.15) and 2.85-fold (95% CI 1.80–4.52) in children with intermediate and slow metabolizer genotypes, respectively. Concomitant antituberculosis treatment increased efavirenz concentrations 1.49-fold (95% CI 1.10–2.01) in children with slow metabolizer genotypes, but did not affect efavirenz concentrations in extensive or intermediate metabolizer genotypes. After adjustment for dose/kg, each kilogram of weight was associated with a 2.8% (95% CI 0.9–4.7) decrease in efavirenz concentrations. Despite higher milligram per kilogram doses, a higher proportion of children in the lowest weight band (10–13.9 kg) had efavirenz concentrations less than 1.0 mg/l than larger children. CONCLUSION: Antituberculosis treatment was not associated with reduced efavirenz concentrations in children, which does not support increased efavirenz doses. Children with slow metabolizer genotype have increased efavirenz concentrations during antituberculosis treatment, likely due to isoniazid inhibiting enzymes involved in accessory metabolic pathways for efavirenz.
OBJECTIVES: An efavirenz-based antiretroviral therapy (ART) regimen is preferred for children more than 3 years of age with tuberculosis. However, rifampin, a key component of antituberculosis therapy, induces CYP2B6. An increased dose of efavirenz is recommended in adults weighing more than 50 kg who require rifampin, but there is scant information in children being treated for tuberculosis. DESIGN: Plasma efavirenz concentrations were compared in 40 children during concomitant treatment for tuberculosis and HIV-1, after stopping rifampicin, and in a control group of children without tuberculosis. Associations with antituberculosis treatment, metabolizer genotype (based on CYP2B6 516G→T, 983T→C, and 15582C→T), weight, and time after dose were evaluated. RESULTS: Compared to children with extensive metabolizer genotypes, efavirenz concentrations were increased 1.42-fold (95% confidence interval, CI 0.94–2.15) and 2.85-fold (95% CI 1.80–4.52) in children with intermediate and slow metabolizer genotypes, respectively. Concomitant antituberculosis treatment increased efavirenz concentrations 1.49-fold (95% CI 1.10–2.01) in children with slow metabolizer genotypes, but did not affect efavirenz concentrations in extensive or intermediate metabolizer genotypes. After adjustment for dose/kg, each kilogram of weight was associated with a 2.8% (95% CI 0.9–4.7) decrease in efavirenz concentrations. Despite higher milligram per kilogram doses, a higher proportion of children in the lowest weight band (10–13.9 kg) had efavirenz concentrations less than 1.0 mg/l than larger children. CONCLUSION: Antituberculosis treatment was not associated with reduced efavirenz concentrations in children, which does not support increased efavirenz doses. Children with slow metabolizer genotype have increased efavirenz concentrations during antituberculosis treatment, likely due to isoniazid inhibiting enzymes involved in accessory metabolic pathways for efavirenz.
Authors: Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron Journal: J Acquir Immune Defic Syndr Date: 2007-06-01 Impact factor: 3.731
Authors: Shabir A Madhi; Sharon Nachman; Avy Violari; Soyeon Kim; Mark F Cotton; Raziya Bobat; Patrick Jean-Philippe; George McSherry; Charles Mitchell Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim Journal: Eur J Clin Pharmacol Date: 2011-11-23 Impact factor: 2.953
Authors: Christoph Wyen; Heidy Hendra; Marco Siccardi; Martin Platten; Hans Jaeger; Thomas Harrer; Stefan Esser; Johannes R Bogner; Norbert H Brockmeyer; Bernhard Bieniek; Juergen Rockstroh; Christian Hoffmann; Albrecht Stoehr; Claudia Michalik; Verena Dlugay; Alexander Jetter; Heribert Knechten; Hartwig Klinker; Adriane Skaletz-Rorowski; Gerd Fätkenheuer; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2011-06-29 Impact factor: 5.790
Authors: S E Starr; C V Fletcher; S A Spector; F H Yong; T Fenton; R C Brundage; D Manion; N Ruiz; M Gersten; M Becker; J McNamara; L M Mofenson; L Purdue; S Siminski; B Graham; D M Kornhauser; W Fiske; C Vincent; H W Lischner; W M Dankner; P M Flynn Journal: N Engl J Med Date: 1999-12-16 Impact factor: 91.245
Authors: Heather J Ribaudo; Huan Liu; Matthias Schwab; Elke Schaeffeler; Michel Eichelbaum; Alison A Motsinger-Reif; Marylyn D Ritchie; Ulrich M Zanger; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David Clifford; David W Haas Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas Journal: Pharmacogenet Genomics Date: 2012-12 Impact factor: 2.089
Authors: Doo-Yeoun Cho; Joan H Q Shen; Suzanne M Lemler; Todd C Skaar; Lang Li; Julia Blievernicht; Ulrich M Zanger; Kwon-Bok Kim; Jae-Gook Shin; David A Flockhart; Zeruesenay Desta Journal: Drug Metab Pharmacokinet Date: 2015-07-29 Impact factor: 3.614
Authors: Anne F Luetkemeyer; Susan L Rosenkranz; Darlene Lu; Beatriz Grinsztejn; Jorge Sanchez; Michael Ssemmanda; Ian Sanne; Helen McIlleron; Diane V Havlir; David W Haas Journal: Clin Infect Dis Date: 2015-02-26 Impact factor: 9.079
Authors: Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Janet W Andersen; Thando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Peter Kim; Courtney V Fletcher Journal: Clin Infect Dis Date: 2015-06-16 Impact factor: 9.079
Authors: Awewura Kwara; Lei Cao; Hongmei Yang; Pamela Poethke; Jaclynn Kurpewski; Karen T Tashima; Behrang D Mahjoub; Michael H Court; Charles A Peloquin Journal: Pharmacotherapy Date: 2014-01-13 Impact factor: 4.705